Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

• Status: Withdrawn
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetes affects almost 21 million people in the United States. In this study we will test a drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat levels after a meal. Lowering high sugar levels and fat levels after a meal is very important in the prevention of the problems that persons with type 2 diabetes often encounter. Hypothesis is that Pramlintide will lower blood sugar and fat levels after a meal.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Collaborator: Amylin Pharmaceuticals, LLC.
• Treatments: Islet Amyloid Polypeptide; Pramlintide

Criteria

Inclusion Criteria:

• Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L)

• Receiving insulin, metformin and/or sulfonylurea/glitinide.

• Maintained on stable anti-hypertensive medication.

• BMI < 52 kg/m2.

• T2DM for at least 3 months with HBA1C under 10%.

Exclusion Criteria:

• Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.

• Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.

• Triglyceride levels > 400 mg/dl.

• BMI > 52 kg/m2.